Company intelligence / Profile preview

COVYDx

Hillsboro, Oregon, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

COVYDx is a private U.S. medical diagnostics company focused on non-invasive point-of-care tests, particularly oral fluid-based rapid diagnostics. The company is best known for CovAbScreen, a saliva/oral-fluid rapid antibody test developed for assessing immune response related to COVID-19. Publicly available sources also indicate COVYDx has intellectual property extending beyond COVID-19 into biomarker-based testing for rheumatoid arthritis. The business appears to be oriented around commercial-stage diagnostic products and a broader rapid testing platform rather than a traditional therapeutic drug pipeline.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Oregon Health & Science University

Beyond the preview

Go deeper on COVYDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVYDx.

Explore the full profile